tradingkey.logo

Glaukos Corp

GKOS
View Detailed Chart
88.350USD
+4.490+5.35%
Close 11/10, 16:00ETQuotes delayed by 15 min
5.07BMarket Cap
LossP/E TTM

Glaukos Corp

88.350
+4.490+5.35%
Intraday
1m
30m
1h
D
W
M
D

Today

+5.35%

5 Days

+1.10%

1 Month

+7.01%

6 Months

-1.79%

Year to Date

-41.08%

1 Year

-37.67%

View Detailed Chart

TradingKey Stock Score of Glaukos Corp

Currency: USD Updated: 2025-11-10

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Glaukos Corp's Score

Industry at a Glance

Industry Ranking
21 / 209
Overall Ranking
86 / 4611
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 16 analysts
Buy
Current Rating
120.500
Target Price
+43.69%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Glaukos Corp Highlights

StrengthsRisks
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 35.57% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 383.48M.
Undervalued
The company’s latest PE is -57.23, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 61.34M shares, increasing 0.38% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 11.62K shares of this stock.

Glaukos Corp News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Glaukos Corp Info

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Ticker SymbolGKOS
CompanyGlaukos Corp
CEOMr. Thomas William Burns
Websitehttps://www.glaukos.com
KeyAI